PTPI

Petros Pharmaceuticals Inc

Add to Watchlist

$

0.000

-0.066(-99.398%)1D

Overview
Forecast
Valuation
Earnings

High

--

Open

--

VWAP

--

Vol

--

Mkt Cap

3.12M

Low

--

Amount

--

EV/EBITDA(TTM)

--

Total Shares

7.00M

EV

7.40M

EV/OCF(TTM)

--

P/S(TTM)

0.19

Petros Pharmaceuticals, Inc. is focused on the self-care market by providing expanded access to key prescription pharmaceuticals such as OTC treatment options. The Company is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions.

Show More

Valuation Metrics

The current forward P/E ratio for Petros Pharmaceuticals Inc (PTPI.O) is -0.00, compared to its 5-year average forward P/E of -0.19. For a more detailed relative valuation and DCF analysis to assess Petros Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-0.19

Current PE

-0.00

Overvalued PE

0.05

Undervalued PE

-0.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.33

Current PS

0.06

Overvalued PS

0.68

Undervalued PS

-0.03

Financials

Annual

Quarterly

FY2024Q4

725.40K

Total Revenue

FY2024Q4

-1.75M

Operating Profit

FY2024Q4

-9.27M

Net Income after Tax

FY2024Q4

-1.07

EPS - Diluted

FY2024Q4

959.96K

Free Cash Flow

FY2024Q4

YoY :

-272.69%

-26.94

Gross Profit Margin - %

FY2024Q4

-51.40

FCF Margin - %

FY2024Q4

YoY :

+811.83%

-1.28K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

0

3-6

Months

0.0

USD

0

6-9

Months

0.0

USD

0

0-12

Months

0.0

USD

0

Bought

0-3

0

0.0

USD

Months

3-6

0

0.0

USD

Months

6-9

0

0.0

USD

Months

0-12

0

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

0

3-6

Months

0.0

Volume

0

6-9

Months

0.0

Volume

0

0-12

Months

0.0

Volume

0

Bought

0-3

0

0.0

Volume

Months

3-6

0

0.0

Volume

Months

6-9

0

0.0

Volume

Months

0-12

0

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

0

3-6

Months

0.0

USD

0

6-9

Months

0.0

USD

0

0-12

Months

0.0

USD

0

Bought

0-3

0

0.0

USD

Months

3-6

0

0.0

USD

Months

6-9

0

0.0

USD

Months

0-12

0

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

0

3-6

Months

0.0

USD

0

6-9

Months

0.0

USD

0

0-12

Months

0.0

USD

0

Bought

0-3

0

0.0

USD

Months

3-6

0

0.0

USD

Months

6-9

0

0.0

USD

Months

0-12

0

0.0

USD

Months

PTPI News & Events

Events Timeline

2025-06-25 (ET)

2025-06-25

09:16:47

Petros Pharmaceuticals announces deconsolidation of Metuchen subsidiary

2025-05-21 (ET)

2025-05-21

09:12:51

Petros Pharmaceuticals announces transition from Nasdaq to OTC Markets

2025-05-20 (ET)

2025-05-20

09:23:05

Petros Pharmaceuticals partners with Innolitics

Sign Up For More Events

Sign Up For More Events

News

9.5

05-21Benzinga

Why Toll Brothers Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

7.5

05-20SeekingAlpha

Petros Pharmaceuticals partners with Innolitics to accelerate SaaS platform development

4.5

04-29Benzinga

US Stocks Mixed; Coca-Cola Posts Upbeat Earnings

Sign Up For More News

People Also Watch

Scinai Immunotherapeutics Ltd

Greenlane Holdings Inc

Interactive Strength Inc

Matinas BioPharma Holdings Inc

Boqii Holding Ltd

Safe & Green Development Corp

Qualigen Therapeutics Inc

BYND Cannasoft Enterprises Inc

FAQ

What is Petros Pharmaceuticals Inc (PTPI) stock price today?

The current price of PTPI is 0 USD — it has decreased -87.35 % in the last trading day.

What is Petros Pharmaceuticals Inc (PTPI)'s business?

What is the price predicton of PTPI Stock?

What is Petros Pharmaceuticals Inc (PTPI)'s revenue for the last quarter?

What is Petros Pharmaceuticals Inc (PTPI)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Petros Pharmaceuticals Inc (PTPI)'s fundamentals?

How many employees does Petros Pharmaceuticals Inc (PTPI). have?

What is Petros Pharmaceuticals Inc (PTPI) market cap?